OLBA DVx HEALTHCAREOLBA DVx HEALTHCARE,Inc.2689東証スタンダード卸売業FY ending Jun 2025, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥1 is left as operating profit. Revenue changed +3.5% from the prior year, operating profit -11.1%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | 1.0% | 2.79× | 2.7% | 4.66× | 12.6% |
| 2022 | 1.4% | 2.82× | 4.0% | 4.56× | 18.3% |
| 2023 | 1.3% | 2.73× | 3.5% | 4.27× | 14.9% |
| 2024 | 1.3% | 2.82× | 3.6% | 4.03× | 14.4% |
| 2025 | 1.2% | 2.75× | 3.2% | 3.94× | 12.6% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Jun 2021 | FY ending Jun 2022 | FY ending Jun 2023 | FY ending Jun 2024 | FY ending Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 102,072 | 107,959 | 110,473 | 118,565 | 122,702 |
| Cost of revenue | 90,473 | 95,455 | 97,518 | 104,964 | 108,793 |
| Gross profit | 11,599 | 12,504 | 12,955 | 13,601 | 13,909 |
| SG&A | 10,059 | 10,431 | 10,803 | 11,374 | 11,929 |
| Operating income | 1,541 | 2,073 | 2,151 | 2,227 | 1,980 |
| Pretax income | 1,513 | 2,137 | 2,157 | 2,243 | 1,920 |
| Income tax | 524 | 601 | 742 | 743 | 490 |
| Net income attributable to owners | 989 | 1,535 | 1,414 | 1,500 | 1,430 |
| Operating margin | 1.5% | 1.9% | 1.9% | 1.9% | 1.6% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Jun 2021 | FY ending Jun 2022 | FY ending Jun 2023 | FY ending Jun 2024 | FY ending Jun 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥2.11B | ¥3.15B | ¥2.36B | ¥2.68B | ¥3.42B |
| Total assets | ¥36.6B | ¥40B | ¥40.9B | ¥43.2B | ¥45.9B |
| Net assets | ¥8.13B | ¥9.09B | ¥10.3B | ¥11.4B | ¥12.3B |
| Share capital | ¥607.8M | ¥607.8M | ¥607.8M | ¥607.8M | ¥607.8M |
| Trade receivables | ¥18.7B | — | — | — | — |
| Property, plant and equipment | ¥4.65B | ¥4.3B | ¥4.25B | ¥4.36B | ¥5.5B |
| Intangible assets excluding goodwill | ¥698.5M | ¥815M | ¥704.7M | ¥646.6M | ¥625.5M |
| Goodwill | — | ¥23M | ¥15.3M | ¥7.7M | — |
| Investment securities | ¥237.6M | ¥223.8M | ¥285.2M | ¥358.5M | ¥368.2M |
| Current assets | ¥29.1B | ¥32.9B | ¥33.7B | ¥35.6B | ¥36.9B |
| Current liabilities | ¥26.1B | ¥28.9B | ¥28.6B | ¥29.7B | ¥29.8B |
| Trade payables | ¥16.3B | ¥18.2B | ¥17.9B | ¥17.8B | ¥18.4B |
| Short-term borrowings | ¥300M | — | ¥900M | ¥600M | — |
| Long-term borrowings | ¥275M | ¥55M | — | — | ¥1.52B |
| Total liabilities | ¥28.4B | ¥30.9B | ¥30.6B | ¥31.9B | ¥33.6B |
| Equity attributable to owners of parent | ¥7.85B | ¥8.92B | ¥10B | ¥10.9B | ¥11.8B |
| Retained earnings | ¥7.14B | ¥8.37B | ¥9.42B | ¥10.5B | ¥11.4B |
| Treasury stock | -¥246.6M | -¥375.9M | -¥342M | -¥557.2M | -¥551.3M |
EDINET (FSA Japan)
有価証券報告書－第76期(2024/07/01－2025/06/30)
EDINET (FSA Japan)
有価証券報告書－第75期(2023/07/01－2024/06/30)
EDINET (FSA Japan)
有価証券報告書－第74期(2022/07/01－2023/06/30)
EDINET (FSA Japan)
有価証券報告書－第73期(令和3年7月1日－令和4年6月30日)
EDINET (FSA Japan)
有価証券報告書－第72期(令和2年7月1日－令和3年6月30日)
EDINET (FSA Japan)
有価証券報告書－第71期(令和1年7月1日－令和2年6月30日)
Extracted from XBRL: 49 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.